Clinical trials: Obesity or Overweight
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.
- Trial name
- NCT06621316
- Testing
- HRS-7535 Tablet
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
The purpose of this study is to evaluate the PK properties of lorcaserin in obese or overweight elderly subjects.
- Trial name
- NCT00828581
- Testing
- lorcaserin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Obesity
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
This study is open to adults with overweight or obesity. People can join the study if they have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more with at least one weight- related health problem.
- Trial name
- NCT07855900
- Testing
- Survodutide
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease.
- Trial name
- NCT06077864
- Testing
- survodutide
- Where
- 542 sites in United States, Argentina and 33 more
- Volunteers
- 5,530 people
- Sponsor
- Boehringer Ingelheim
Obesity & Overweight
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections.
- Trial name
- NCT04940078
- Testing
- Cagrilintide, semaglutide, Cagrilintide and semaglutide
- Where
- 2 sites in Canada, Denmark
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the…
- Trial name
- NCT07294235
- Testing
- BGM1812
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight.
- Trial name
- TRIUMPH-9 (NCT07357415)
- Testing
- Retatrutide
- Where
- 35 sites in United States, Argentina and 1 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients
This is a randomized, double-blind, placebo-controlled, dose-finding, Phase 2a study designed to evaluate the safety and efficacy of KDS2010 in overweight or obese patients.
- Conditions
- Overweight, Obesity, Obese Patients
- Trial name
- NCT07009171
- Testing
- KDS2010
- Where
- 3 sites in South Korea
- Volunteers
- 75 people
- Sponsor
- NeuroBiogen Co., Ltd
Obesity
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as…
- Trial name
- NCT03198767
- Testing
- LIK066, Carbohydrate 50%, Carbohydrate 25%
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for healthy subjects with overweight or obesity
- Trial name
- NCT06739707
- Testing
- MD-18
- Where
- Israel
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cohen Global, Ltd.
Obesity, Overweight or Obesity
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks.
- Trial name
- VESPER-1 (NCT06712836)
- Testing
- MET097
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Obesity
Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients. Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist…
- Trial name
- NCT00325546
- Testing
- Rimonabant (SR141716)
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Ulcerative Colitis, Obesity or Overweight
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and…
- Trial name
- COMMIT-UC (NCT06937086)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 186 sites in United States, Austria and 21 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Obesity, Behavior, Health
Coached or Non-Coached Weight Loss Intervention
To evaluate the effect of one-on-one coaching in the Noom Healthy Weight Program, a digital behavior change, weight loss intervention, compared to the same program with no coaching, as well as influential factors.
- Conditions
- Obesity, Behavior, Health, Behavior, Eating, Weight Loss
- Trial name
- NCT04645108
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching, Noom Healthy Weight; mobile behavior change program for weight loss
- Where
- United States
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Obesity, Diabetes Mellitus, Type 2
A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin
The purpose of this study is to evaluate the effectiveness and safety of a topiramate controlled-release formulation in the treatment of obese, type 2 diabetic patients managed with diet alone or combined with metformin.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231647
- Testing
- topiramate
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity or Overweight
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide.
- Trial name
- REDEFINE 6 (NCT05996848)
- Testing
- Cagrilintide, Semaglutide
- Where
- 37 sites in China
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Weight Loss in Adults Using Semaglutide (Real-world Study)
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
- Trial name
- NCT07627074
- Testing
- Semaglutide
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 237,211 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight or Obesity
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo.
- Trial name
- VESPER-3 (NCT06973720)
- Testing
- MET097
- Where
- 6 sites in United States
- Volunteers
- 268 people
- Sponsor
- Pfizer